The Gastroparesis drugs in development market research report provides comprehensive information on the therapeutics under development for Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gastroparesis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gastroparesis and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Gastroparesis by 16 companies/universities/institutes. The top development phase for Gastroparesis is preclinical with seven drugs in that stage. The Gastroparesis pipeline has 18 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Gastroparesis pipeline products market are: RosVivo Therapeutics, Vogenx and Processa Pharmaceuticals.
The key targets in the Gastroparesis pipeline products market include D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 4, and D3 Dopamine Receptor.
The key mechanisms of action in the Gastroparesis pipeline product include 5-Hydroxytryptamine Receptor 4 Agonist with four drugs in Phase III. The Gastroparesis pipeline products include two routes of administration with the top ROA being Oral and six key molecule types in the Gastroparesis pipeline products market including Small Molecule, and Synthetic Peptide.
Gastroparesis overview
Gastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from stomach to small intestine, even though there is no blockage in the stomach or intestines. The symptoms of gastroparesis may include feeling full shortly after starting a meal, feeling full long after eating a meal, nausea, and vomiting. Diabetes is the most common known cause of gastroparesis.
For a complete picture of Gastroparesis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
